Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib
Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE (palbociclib) and talazoparib in Combination with CB-839
pharmaceutical investing Calithera Biosciences Reports Fourth Quarter 2017 Financial Results and Recent Highlights
Canadian Gold Resources to Expand Maiden Diamond Drill Program & Provides Update on Bulk Sampling Program at Lac Arsenault, LIFE Offering Update; Disclosure Corrections
Emerita Intersects 9.6 Meters Grading 2.7% Copper, 1.85 g/t Gold and 6.9 Meters Grading 1.4% Copper, 1.85 g/t Gold at El Cura Deposit
